Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 2, 2007 - Issue 4
Submit an article Journal homepage
131
Views
5
CrossRef citations to date
0
Altmetric
Reviews

Conotoxin therapeutics: a pipeline for success?

Marianne A Grant Division of Molecular and Vascular Medicine, Department of Medicine, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. [email protected]
,
Kumaran Shanmugasundaram Division of Molecular and Vascular Medicine, Department of Medicine, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. [email protected]
&
Alan C Rigby Division of Molecular and Vascular Medicine, Department of Medicine, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. [email protected]; Mount Desert Island Biological Laboratory, Salisbury Cove, ME 04672, USA
Pages 453-468 | Published online: 14 May 2007

Bibliography

  • DOKOUMETZIDIS A, AARONS L: Propagation of population PK and PD information using a bayesian approach: dealing with non-exchangeability. J. Pharmacokinet. Pharmacodyn. (2006) 33:29-48.
  • DOKOUMETZIDIS A, KARALIS V, ILIADIS A et al.: The heterogeneous course of drug transit through the body. Trends Pharmacol. Sci. (2004) 25:140-146.
  • DOKOUMETZIDIS A, KOSMIDIS K, ARGYRAKIS P et al.: Modeling and monte carlo simulations in oral drug absorption. Basic Clin. Pharmacol. Toxicol. (2005) 96:200-205.
  • DI L, KERNS EH: Profiling drug-like properties in discovery research. Curr. Opin. Chem. Biol. (2003) 7:402-408.
  • LIPINSKI CA: Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. (2000) 44:235-249.
  • SILLERUD LO, LARSON RS: Design and structure of peptide and peptidomimetic antagonists of protein–protein interaction. Curr. Protein Pept. Sci. (2005) 6:151-169.
  • HUMMEL G, REINEKE U, REIMER U: Translating peptides into small molecules. Molecular BioSystems (2006) 2:499-508.
  • ORIVE G, GASCON AR, HERNANDEZ RM et al.: Techniques: new approaches to the delivery of biopharmaceuticals. Trends Pharmacol. Sci. (2004) 25:382-387.
  • FRY DC,VASSILEV LT: Targeting protein–protein interactions for cancer therapy. J. Mol. Med. (2005).
  • VASSILEV LT, VU BT, GRAVES B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of mdm2. Science (2004) 303:844-848.
  • OLIVERA BM: E.E. Just lecture, 1996. Conus venom peptides, receptor and ion channel targets, and drug design: 50 million years of neuropharmacology. Mol. Biol. Cell. (1997) 8:2101-2109.
  • OLIVERA BM, RIVIER J, CLARK C et al.: Diversity of conus neuropeptides. Science. (1990) 249:257-263.
  • LIVETT BG, GAYLER KR, KHALIL Z: Drugs from the sea: conopeptides as potential therapeutics. Curr. Med. Chem. (2004) 11:1715-1723.
  • NORTON RS, OLIVERA BM: Conotoxins down under. Toxicon. (2006) 48:780-798.
  • OLIVERA BM: Conus peptides: Biodiversity-based discovery and exogenomics. J. Biol. Chem. (2006) 281:31173-31177.
  • BANDYOPADHYAY PK, GARRETT JE, SHETTY RP et al.: γ-glutamyl carboxylation: an extracellular posttranslational modification that antedates the divergence of molluscs, arthropods, and chordates. Proc. Natl. Acad. Sci. USA (2002) 99:1264-1269.
  • ESPIRITU DJ, WATKINS M, DIA-MONJE V et al.: Venomous cone snails: molecular phylogeny and the generation of toxin diversity. Toxicon. (2001) 39:1899-1916.
  • OLIVERA BM, WALKER C, CARTIER GE et al.: Speciation of cone snails and interspecific hyperdivergence of their venom peptides. Potential evolutionary significance of introns. Ann. NY Acad. Sci. (1999) 870:223-237.
  • WOODWARD SR, CRUZ LJ, OLIVERA BM et al.: Constant and hypervariable regions in conotoxin propeptides. Embo J. (1990) 9:1015-1020.
  • HASSON A, SHON KJ, OLIVERA BM et al.: Alterations of voltage-activated sodium current by a novel conotoxin from the venom of conus gloriamaris. J. Neurophysiol. (1995) 73:1295-1301.
  • HAMMAN JH, ENSLIN GM, KOTZE AF: Oral delivery of peptide drugs: barriers and developments. BioDrugs (2005) 19:165-177.
  • BUCZEK O, BULAJ G, OLIVERA BM: Conotoxins and the posttranslational modification of secreted gene products. Cell. Mol. Life Sci.. (2005) 62:3067-3079.
  • GRANT MA, MORELLI XJ, RIGBY AC: Conotoxins and structural biology: a prospective paradigm for drug discovery. Curr. Protein Pept. Sci. (2004) 5:235-248.
  • FRANCO A, PISAREWICZ K, MOLLER C et al.: Hyperhydroxylation: a new strategy for neuronal targeting by venomous marine molluscs. Prog. Mol. Subcell. Biol. (2006) 43:83-103.
  • HURKO O, RYAN JL: Translational research in central nervous system drug discovery. NeuroRx (2005) 2:671-682.
  • BLACK MD: Therapeutic potential of positive ampa modulators and their relationship to ampa receptor subunits. A review of preclinical data. Psychopharmacology (Berl). (2005) 179:154-163.
  • PALMER AM, STEPHENSON FA: CNS drug discovery: challenges and solutions. Drug News Perspect. (2005) 18:51-57.
  • GAYLER K, SANDALL D, GREENING D et al.: Molecular prospecting for drugs from the sea. Isolating therapeutic peptides and proteins from cone snail venom. IEEE Eng. Med. Biol. Mag. (2005) 24:79-84.
  • LIVETT BG, SANDALL DW, KEAYS D et al.: Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor. Toxicon. (2006) 48:810-829.
  • VADALOUCA A, SIAFAKA I, ARGYRA E et al.: Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. Ann. NY Acad. Sci. (2006) 1088:164-186.
  • MILJANICH GP: Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. (2004) 11:3029-3040.
  • STAATS PS, YEARWOOD T, CHARAPATA SG et al.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or aids: a randomized controlled trial. JAMA (2004) 291:63-70.
  • ENDEAN R: Venomous cones. Aust. Nat. Hist. (1964) 14:400-403.
  • GARBER K: Peptide leads new class of chronic pain drugs. Nat. Biotechnol. (2005) 23:399.
  • ZAMPONI GW: New frontiers in managing chronic pain. Curr. Top. Med. Chem. (2005) 5:527.
  • JONES RM, BULAJ G: Conotoxins - new vistas for peptide therapeutics. Curr. Pharm. Des. (2000) 6:1249-1285.
  • FRANEY T: Novel compounds drive the market for neuropathic pain therapies 10 $1.25 billion by 2012. WWMR inc (2006).
  • WERMELING D, DRASS M, ELLIS D et al.: Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J. Clin. Pharmacol. (2003) 43:624-636.
  • HEADING CE: Ziconotide (ELAN pharmaceuticals). IDrugs (2001) 4:339-350.
  • WALLACE MS: Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev. Neurother. (2006) 6:1423-1428.
  • RAUCK RL, WALLACE MS, LEONG MS et al.: A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J. Pain Symptom Manage. (2006) 31:393-406.
  • SNUTCH TP: Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx (2005) 2:662-670.
  • CAO YQ: Voltage-gated calcium channels and pain. Pain. (2006) 126:5-9.
  • MCINTOSH JM, OLIVERA BM, CRUZ LJ et al.: Gamma-carboxyglutamate in a neuroactive toxin. J. Biol. Chem. (1984) 259:14343-14346.
  • MYERS RA, MCINTOSH JM, IMPERIAL J: Peptides from conus venoms which affect Ca2+ entry into neurons. J. Toxicol. Toxin Reviews (1990) 9:179-202.
  • SKOLNICK P, BOJE K, MILLER R et al.: Noncompetitive inhibition of N-methyl-d-aspartate by conantokin-g: Evidence for an allosteric interaction at polyamine sites. Journal of Neurochemistry (1992) 59:1516-1521.
  • CHANDLER P, PENNINGTON M, MACCECCHINI ML et al.: Polyamine-like actions of peptides derived from conantokin-g, an N-methyl-d-aspartate (nmda) antagonist. J. Biol. Chem. (1993) 268:17173-17178.
  • ZHOU LM, SZENDREI GI, FOSSOM LH et al.: Synthetic analogues of conantokin-g: NMDA antagonists acting through a novel polyamine-coupled site. J. Neurochem. (1996) 66:620-628.
  • RIGBY AC, BALEJA JD, FURIE BC et al.: Three-dimensional structure of a gamma-carboxyglutamic acid-containing conotoxin, conantokin g, from the marine snail conus geographus: the metal-free conformer. Biochemistry (1997) 36:6906-6914.
  • RIGBY AC, BALEJA JD, LI L et al.: Role of gamma-carboxyglutamic acid in the calcium-induced structural transition of conantokin G, a conotoxin from the marine snail conus geographus. Biochem. (1997) 36:15677-15684.
  • SKJAERBAEK N, NIELSEN KJ, LEWIS RJ et al.: Determination of the solution structures of conantokin-G and conantokin-T by CD and NMR spectroscopy. J. Biol. Chem. (1997) 272:2291-2299.
  • CHEN Z, BLANDL T, PROROK M et al.: Conformational changes in conantokin-g induced upon binding of calcium and magnesium as revealed by nmr structural analysis. J. Biol. Chem. (1998) 273:16248-16258.
  • MALMBERG AB, GILBERT H, MCCABE RT et al.: Powerful antinociceptive effects of the cone snail venom-derived subtype-selective nmda receptor antagonists conantokins G and T. Pain (2003) 101:109-116.
  • ALONSO D, KHALIL Z, SATKUNANTHAN N et al.: Drugs from the sea: conotoxins as drug leads for neuropathic pain and other neurological conditions. Mini Rev. Med. Chem. (2003) 3:785-787.
  • BOGIN O: Venom peptides and their mimetics as potential drug Modulator. (2005) 19:14-20.
  • CRAIG AG, NORBERG T, GRIFFIN D et al.: Contulakin-G, an O-glycosylated invertebrate neurotensin. J. Biol. Chem. (1999) 274:13752-13759.
  • LEWIS RJ, GARCIA ML: Therapeutic potential of venom peptides. Nat. Rev. Drug Discov. (2003) 2:790-802.
  • KANG J, LOW W, NORBERG T et al.: Total chemical synthesis and NMR characterization of the glycopeptide tx5a, a heavily post-translationally modified conotoxin, reveals that the glycan structure is α-d-gal-(1-->3)-α-d-galnac. Eur. J. Biochem. (2004) 271:4939-4949.
  • SANDALL DW, SATKUNANATHAN N, KEAYS DA et al.: A novel alpha-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry (2003) 42:6904-6911.
  • JAKUBOWSKI JA, KEAYS DA, KELLEY WP et al.: Determining sequences and post-translational modifications of novel conotoxins in conus victoriae using cdna sequencing and mass spectrometry. J. Mass Spectrom. (2004) 39:548-557.
  • CHIVIAN E, ROBERTS CM, BERNSTEIN AS: The threat to cone snails. Science (2003) 302:391.
  • DUDA TF, JR., BINGHAM JP, LIVETT BG et al.: How much at risk are cone snails? Science. (2004) 303:955-957; author reply 955-957.
  • OLIVERA BM, RIVIER J, SCOTT JK et al.: Conotoxins. J. Biol. Chem. (1991) 266:22067-22070.
  • LANG PM, BURGSTAHLER R, HABERBERGER RV et al.: A conus peptide blocks nicotinic receptors of unmyelinated axons in human nerves. Neuroreport. (2005) 16:479-483.
  • SATKUNANATHAN N, LIVETT B, GAYLER K et al.: Alpha-conotoxin vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res. (2005) 1059:149-158.
  • RESSLER KJ, NEMEROFF CB: Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry. (1999) 46:1219-1233.
  • MCINTOSH JM, CORPUZ GO, LAYER RT et al.: Isolation and characterization of a novel conus peptide with apparent antinociceptive activity. J. Biol. Chem. (2000) 275:32391-32397.
  • NIELSEN CK, LEWIS RJ, ALEWOOD D et al.: Anti-allodynic efficacy of the chi-conopeptide, xen2174, in rats with neuropathic pain. Pain. (2005) 118:112-124.
  • ADAMS DJ, SMITH AB, SCHROEDER CI et al.: Omega-conotoxin cvid inhibits a pharmacologicly distinct voltage-sensitive calcium channel associated with transmitter release from preganglionic nerve terminals. J. Biol. Chem. (2003) 278:4057-4062.
  • SMITH MT, CABOT PJ, ROSS FB et al.: The novel N-type calcium channel blocker, am336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance p release in rat spinal cord slices. Pain. (2002) 96:119-127.
  • SCHROEDER CI, DOERING CJ, ZAMPONI GW et al.: N-type calcium channel blockers: novel therapeutics for the treatment of pain. Med. Chem. (2006) 2:535-543.
  • BAJORATH J: Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov. (2002) 1:882-894.
  • BOCK JR, GOUGH DA: A new method to estimate ligand-receptor energetics. Mol. Cell Proteomics. (2002) 1:904-910.
  • GODDEN JW, FURR JR, XUE L et al.: Molecular similarity analysis and virtual screening by mapping of consensus positions in binary-transformed chemical descriptor spaces with variable dimensionality. J. Chem. Inf. Comput. Sci. (2004) 44:21-29.
  • KITCHEN DB, DECORNEZ H, FURR JR et al.: Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat. Rev. Drug Discov. (2004) 3:935-949.
  • SHOICHET BK: Virtual screening of chemical libraries. Nature. (2004) 432:862-865.
  • MORELLI X, RIGBY AC: Acceleration of the drug discovery process: a combinatorial approach using nmr spectroscopy and virtual screening. Cur. Comp-Aid. Drug Design. (2007) In Press.
  • GRADL SN, FELIX JP, ISACOFF EY et al.: Protein surface recognition by rational design: Nanomolar ligands for potassium channels. J. Am. Chem. Soc. (2003) 125:12668-12669.
  • JAIN R, CHAWRAI S: Advancements in the anti-diabetes chemotherapeutics based on amino acids, peptides, and peptidomimetics. Mini Rev. Med. Chem. (2005) 5:469-477.
  • LEDUC AM, TRENT JO, WITTLIFF JL et al.: Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc. Natl. Acad. Sci. USA (2003) 100:11273-11278.
  • WATT PM: Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat. Biotechnol. (2006) 24:177-183.
  • YIN H, LEE GI, SEDEY KA et al.: Terphenyl-based bak bh3 alpha-helical proteomimetics as low-molecular-weight antagonists of bcl-xl. J. Am. Chem. Soc. (2005) 127:10191-10196.
  • LUBBERS NL, CAMPBELL TJ, POLAKOWSKI JS et al.: Postischemic administration of CGX-1051, a peptide from cone snail venom, reduces infarct size in both rat and dog models of myocardial ischemia and reperfusion. J. Cardiovasc. Pharmacol. (2005) 46:141-146.
  • ZHANG SJ, YANG XM, LIU GS et al.: CGX-1051, a peptide from conus snail venom, attenuates infarction in rabbit hearts when administered at reperfusion. J. Cardiovasc. Pharmacol. (2003) 42:764-771.
  • NORTON RS, PENNINGTON MW, WULFF H: Potassium channel blockade by the sea anemone toxin SHK for the treatment of multiple sclerosis and other autoimmune diseases. Curr. Med. Chem. (2004) 11:3041-3052.
  • JACOBSEN RB, KOCH ED, LANGE-MALECKI B et al.: Single amino acid substitutions in kappa-conotoxin pviia disrupt interaction with the shakerK+ channel. J. Biol. Chem. (2000) 275:24639-24644.
  • WITT KA, DAVIS TP: CNS drug delivery: opioid peptides and the blood-brain barrier. Aaps J. (2006) 8:E76-88.
  • BARR RK, BOEHM I, ATTWOOD PV et al.: The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of jnk. J. Biol. Chem. (2004) 279:36327-36338.
  • BARR RK, HOPKINS RM, WATT PM et al.: Reverse two-hybrid screening identifies residues of jnk required for interaction with the kinase interaction motif of jnk-interacting protein-1. J. Biol. Chem. (2004) 279:43178-43189.
  • MATTHEWS T, SALGO M, GREENBERG M et al.: Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host cd4 lymphocytes. Nat. Rev. Drug Discov. (2004) 3:215-225.
  • CHAN B, GREENAN G, MCKEON F et al.: Identification of a peptide fragment of dscr1 that competitively inhibits calcineurin activity in vitro and in vivo. Proc. Natl Acad. Sci. USA (2005) 102:13075-13080.
  • HANSSON K, MA X., ELIASSON L et al.: The first gla-containing contryphan: a selective l-type calcium ion channel blocker isolated from the venom of conus marmoreus. J. Biol. Chem. (2004) 279:32453-32463.
  • BUCZEK O, YOSHIKAMI D, WATKINS M et al.: Characterization of d-amino-acid-containing excitatory conotoxins and redefinition of the i-conotoxin superfamily. Febs J. (2005) 272:4178-4188.
  • LOVELACE ES, ARMISHAW CJ, COLGRAVE ML et al.: Cyclic mria: a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter. J. Med. Chem. (2006) 49:6561-6568.
  • NICKE A, SAMOCHOCKI M, LOUGHNAN ML et al.: α-Conotoxins epi and auib switch subtype selectivity and activity in native versus recombinant nicotinic acetylcholine receptors. FEBS Lett. (2003) 554:219-223.
  • QUIRAM PA, SINE SM: Structural elements in α-conotoxin imi essential for binding to neuronal α7 receptors. J. Biol. Chem. (1998) 273:11007-11011.
  • NICKE A, LOUGHNAN ML, MILLARD EL et al.: Isolation, structure, and activity of gid, a novel α 4/7-conotoxin with an extended N-terminal sequence. J. Biol. Chem. (2003) 278:3137-3144.
  • KASHEVEROV IE, ZHMAK MN, VULFIUS CA et al.: α-Conotoxin analogs with additional positive charge show increased selectivity towards torpedo californica and some neuronal subtypes of nicotinic acetylcholine receptors. Febs J. (2006) 273:4470-4481.
  • DEECHONGKIT S, KELLY JW: The effect of backbone cyclization on the thermodynamics of beta-sheet unfolding: Stability optimization of the pin ww domain. J. Am. Chem. Soc. (2002) 124:4980-4986.
  • DEECHONGKIT S, NGUYEN H, POWERS ET et al.: Context-dependent contributions of backbone hydrogen bonding to beta-sheet folding energetics. Nature. (2004) 430:101-105.
  • DEECHONGKIT S, POWERS ET, YOU SL et al.: Controlling the morphology of cross beta-sheet assemblies by rational design. J. Am. Chem. Soc. (2005) 127:8562-8570.
  • CLARK RJ, FISCHER H, DEMPSTER L et al.: Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII. Proc. Natl. Acad. Sci. USA (2005) 102:13767-13772.
  • HRUBY VJ, BALSE PM: Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr. Med. Chem. (2000) 7:945-970.
  • YIN H, HAMILTON AD: Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem. Int. Ed. Engl. (2005) 44:4130-4163.
  • BODEN P, EDEN JM, HODGSON J et al.: Use of a dipeptide chemical library in the development of non-peptide tachykinin NK3 receptor selective antagonists. J. Med. Chem. (1996) 39:1664-1675.
  • HORWELL D, PRITCHARD M, RAPHY J et al.: 'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors. Immunopharmacology. (1996) 33:68-72.
  • HORWELL DC, HOWSON W, RATCLIFFE GS et al.: The design of dipeptide helical mimetics: the synthesis, tachykinin receptor affinity and conformational analysis of 1,1,6-trisubstituted indanes. Bioorg. Med. Chem. (1996) 4:33-42.
  • ORNER BP, ERNST JT, HAMILTON AD: Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. J. Am. Chem. Soc. (2001) 123:5382-5383.
  • WALENSKY LD, KUNG AL, ESCHER I et al.: Activation of apoptosis in vivo by a hydrocarbon-stapled bh3 helix. Science. (2004) 305:1466-1470.
  • WALENSKY LD, PITTER K, MORASH Jet al.: A stapled bid bh3 helix directly binds and activates bax. Mol Cell. (2006) 24:199-210.
  • ZHAO L, CHMIELEWSKI J: Inhibiting protein-protein interactions using designed molecules. Curr. Opin. Struct. Biol. (2005) 15:31-34.
  • PELLECCHIA M, SEM DS, WUTHRICH K: NMR in drug discovery. Nat. Rev. Drug Discov. (2002) 1:211-219.
  • ABRAHAMIAN E, FOX PC, NAERUM L et al.: Efficient generation, storage, and manipulation of fully flexible pharmacophore multiplets and their use in 3-D similarity searching. J. Chem. Inf. Comput. Sci. (2003) 43:458-468.
  • MARTIN YC: 3D database searching in drug design. J. Med. Chem. (1992) 35:2145-2154.
  • RIPKA AS, RICH DH: Peptidomimetic design. Curr. Opin. Chem. Biol. (1998) 2:441-452.
  • RIPKA AS, SATYSHUR KA, BOHACEK RS et al.: Aspartic protease inhibitors designed from computer-generated templates bind as predicted. Org Lett. (2001) 3:2309-2312.
  • DEBNATH AK: Quantitativestructure-activity relationship (QSAR) paradigm--Hansch era to newmillennium. Mini Rev. Med. Chem. (2001) 1:187-195.
  • FRANKE L, BYVATOV E, WERZ O et al.: Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors. J. Med. Chem. (2005) 48:6997-7004.
  • TSUCHIDA K, CHAKI H, TAKAKURA T et al.: Discovery of nonpeptidic small-molecule ap-1 inhibitors: Lead hopping based on a three-dimensional pharmacophore model. J. Med. Chem. (2006) 49:80-91.
  • SCHNEIDER G, FECHNER U: Computer-based de novo design of drug-like molecules. Nat. Rev. Drug. Discov. (2005) 4:649-663.
  • BAELL JB, FORSYTH SA, GABLE RW et al.: Design and synthesis of type-iii mimetics of omega-conotoxin gvia. J. Comput. Aided Mol. Des. (2001) 15:1119-1136.
  • MASSILIA GR, ELISEO T, GROLLEAU F et al.: Contryphan-vn: a modulator of Ca2+-dependent K+ channels. Biochem. Biophys. Res. Commun. (2003) 303:238-246.
  • HANSSON K, FURIE B, FURIE BC et al.: Isolation and characterization of three novel gla-containing conus marmoreus venom peptides, one with a novel cysteine pattern. Biochem. Biophys. Res. Commun. (2004) 319:1081-1087.
  • PALLAGHY PK, NORTON RS: The cyclic contryphan motif cpxxpxc, a robust scaffold potentially useful as an omega-conotoxin mimic. Biopolymers. (2000) 54:173-179.
  • PALLAGHY PK, MELNIKOVA AP, JIMENEZ EC et al.: Solution structure of contryphan-r, a naturally occurring disulfide- bridged octapeptide containing d-tryptophan: comparison with protein loops. Biochemistry. (1999) 38:11553-11559.
  • MASSILIA GR, SCHININA ME, ASCENZI P et al.: Contryphan-vn: a novel peptide from the venom of the mediterranean snail conus ventricosus. Biochem. Biophys. Res. Commun. (2001) 288:908-913.
  • GRANT MA, HANSSON K, FURIE BC et al.: The metal-free and calcium-bound structures of a gamma-carboxyglutamic acid-containing contryphan from conus marmoreus, glacontryphan-M. J. Biol. Chem. (2004) 279:32464-32473.
  • ELISEO T, CICERO DO, ROMEO C et al.: Solution structure of the cyclic peptide contryphan-vn, a Ca2+-dependent K+ channel modulator. Biopolymers. (2004) 74:189-198.
  • MITTERDORFER J, GRABNER M, KRAUS RLet al.: Molecular basis of drug interaction with l-type Ca2+ channels. J. Bioenerg. Biomembr. (1998) 30:319-334.
  • IRWIN JJ, SHOICHET BK: Zinc – a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. (2005) 45:177-182.
  • SINGH J, ADAMS S, CARTER MB et al.: Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma. Curr. Top Med. Chem. (2004) 4:1497-1507.
  • SINGH J, VAN VLIJMEN H, LEE WC et al.: 3D QSAR (comfa) of a series of potent and highly selective VLA-4 antagonists. J. Comput. Aided Mol. Des. (2002) 16:201-211.
  • SCHROEDER CI, SMYTHE ML, LEWIS RJ: Development of small molecules that mimic the binding of omega-conotoxins at the N-type voltage-gated calcium channel. Mol. Divers. (2004) 8:127-134.
  • HANSCH C, MALONEY, PP, FUJITA T, MUIR RM: Correlation of biological activity of phenoxyacetic acids with hammett substituent constants and partition coefficients. Nature (1962) 194:178-180.
  • PARDRIDGE WM: The blood–brain barrier: bottleneck in brain drug development. NeuroRx (2005) 2:3-14.
  • SU Y, SINKO PJ: Drug delivery across the blood-brain barrier: why is it difficult? How to measure and improve it? Expert Opin. Drug Deliv. (2006) 3:419-435.
  • LIEDERER BM, FUCHS T, VANDER VELDE D et al.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J. Med. Chem (2006) 49:1261-1270.
  • DREWS J: Drug discovery: a historical perspective. Science (2000) 287:1960-1964.
  • DREWS J, RYSER S: The role of innovation in drug development. Nat. Biotechnol. (1997) 15:1318-1319.
  • BRADFORD JR, WESTHEAD DR: Improved prediction of protein–protein binding sites using a support vector machines approach. Bioinformatics (2005) 21:1487-1494.
  • FOLKERS GE, VAN BUUREN BN, KAPTEIN R: Expression screening, protein purification and NMR analysis of human protein domains for structural genomics. J. Struct. Funct. Genomics (2004) 5:119-131.
  • LUNDSTROM K: Structural genomics on membrane proteins: mini review. Comb. Chem. High Throughput Screen (2004) 7:431-439.
  • DREWS II: Drug discovery today – and tomorrow. Drug Discov. Today (2000) 5:2-4.
  • CHEN L, YIN H, FAROOQI B et al.: P53 α-helix mimetics antagonize p53/MDM2 interaction and activate p53. Mol. Cancer Ther. (2005) 4:1019-1025.
  • ARKIN MR, RANDAL M, DELANO WL et al.: Binding of small molecules to an adaptive protein–protein interface. Proc. Natl. Acad. Sci USA (2003) 100:1603-1608.
  • ARKIN MR, WELLS JA: Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. (2004) 3:301-317.

Websites

  • http//:www.blasterdocking.org/zinc5 IRWIN JJ, SHOICHET BK: A free database of commercially available compounds for virtual ccreening. J. Chem. Inf. Model (2005) 45:177-182.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.